A hemoglobin-based oxygen carrier sensitized Cisplatin based chemotherapy in hepatocellular carcinoma.

Autor:	Qi X; Department of Surgery, The University of Hong Kong, Hong Kong, China., Wong BL; New β Innovation Limited, 18/F Chevalier Commercial Centre, Hong Kong, China., Lau SH; New β Innovation Limited, 18/F Chevalier Commercial Centre, Hong Kong, China., Ng KT; Department of Surgery, The University of Hong Kong, Hong Kong, China., Kwok SY; New β Innovation Limited, 18/F Chevalier Commercial Centre, Hong Kong, China., Kin-Wai Sun C; New β Innovation Limited, 18/F Chevalier Commercial Centre, Hong Kong, China., Tzang FC; New β Innovation Limited, 18/F Chevalier Commercial Centre, Hong Kong, China., Shao Y; Department of Surgery, The University of Hong Kong, Hong Kong, China., Li CX; Department of Surgery, The University of Hong Kong, Hong Kong, China., Geng W; Department of Surgery, The University of Hong Kong, Hong Kong, China., Ling CC; Department of Surgery, The University of Hong Kong, Hong Kong, China., Ma YY; Department of Surgery, The University of Hong Kong, Hong Kong, China., Liu XB; Department of Surgery, The University of Hong Kong, Hong Kong, China., Liu H; Department of Surgery, The University of Hong Kong, Hong Kong, China., Liu J; Department of Surgery, The University of Hong Kong, Hong Kong, China., Yeung WH; Department of Surgery, The University of Hong Kong, Hong Kong, China., Lo CM; Department of Surgery, The University of Hong Kong, Hong Kong, China.; Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China., Man K; Department of Surgery, The University of Hong Kong, Hong Kong, China.; Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China.
Jazyk:	angličtina
Zdroj:	Oncotarget [Oncotarget] 2017 Jul 28; Vol. 8 (49), pp. 85311-85325. Date of Electronic Publication: 2017 Jul 28 (Print Publication: 2017).
DOI:	10.18632/oncotarget.19672
Abstrakt:	Background and Objective: Our previous study showed that liver graft injury not only promotes tumor recurrence, but also induces chemoresistance in recurrent HCC after liver transplantation. Recently, we found that the hemoglobin-based oxygen carrier"YQ23" significantly ameliorates hepatic IR injury and prevent tumor recurrence. Here, we intended to explore the novel therapeutic strategy using oxygen carrier "YQ23"to sensitize chemotherapy in HCC. Methods: To investigate the role of YQ23 combined with Cisplatin, the proliferation of HCC cells was examined under combined treatment by MTT and colony formation. To explore the effect of YQ23 on sensitization of Cisplatin based chemotherapy, the orthotopic liver cancer model was established. To characterize the delivery of YQ23 in tumor tissue, the intravital imaging system was applied for longitudinal observation in ectopic liver cancer model. The distribution of YQ23 was examined by IVIS spectrum. Results: YQ23 significantly suppressed the proliferation of HCC cells under Cisplatin treatment in a dose and time dependent manner. Moreover, YQ23 administration significantly sensitized Cisplatin based chemotherapy in orthotopic liver cancer model. Down-regulation of DHFR may be one of the reasons for YQ23 sensitizing Cisplatin based chemotherapy. Real-time intravital imaging showed that YQ23 accumulated in the tumor tissue and maintained as long as 3 days in ectopic liver cancer model. The IVIS spectrum examination showed that YQ23 distributed mainly at liver and bladder within the first 36 hours after administration in orthotopic liver cancer model. Conclusion: YQ23 treatment may be a potential therapeutic strategy to sensitize chemotherapy in HCC. Competing Interests: CONFLICTS OF INTEREST The YQ23 product is provided by New β Innovation Limited.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu